



EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

AEROMEDICAL STUDY DE-RISKS RURAL AND REMOTE STROKE USE CASE

Key Highlights

- **Successful completion of the First Responder Brain Scanner's aeromedical feasibility and usability study with the Royal Flying Doctor Service supports deployment in pre-hospital settings**
- **Results demonstrated the First Responder device can be deployed and operated effectively across a range of real-world environments.**
- **The study received positive operator and patient feedback, and the quality of scan data from patients across 13 transfers was unaffected by flight conditions.**
- **Results de-risk the device's rural and remote stroke care use cases and support progression to production equivalent commercial units. These units will underpin upcoming data collection alongside diagnostic performance and substantial equivalence testing to support regulatory clearance.**
- **EMVision has received the final \$400,000 non-dilutive milestone payment under its Australian Stroke Alliance Project Agreement.**

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company") is pleased to provide results from the feasibility and usability study evaluating the First Responder Brain Scanner in an aeromedical retrieval setting. The study was conducted in collaboration with the Royal Flying Doctor Service (RFDS), Australian Stroke Alliance (ASA) and South Australian Ambulance Service (SAAS).

The study was a single-arm, workflow integration study designed to assess the operational feasibility and usability of the First Responder Brain Scanner deployed by the Royal Flying Doctor's aeromedical retrieval and research teams. The study enrolled 17 adult participants who were undergoing aeromedical transport. The device was dispatched on 15 transfers across 12 unique airstrips spanning 125km to 371 km from Adelaide Airport. Scans were conducted across a range of real-world environments including tarmac, on-board stationary aircraft, and clinic settings, providing important insight into device deployment under real world conditions.

Key findings

Royal Flying Doctor Service flight nurses, the device's end users in the study, completed a usability survey and rated the First Responder favourably across domains of device preparation, patient set-up and scanner operation. The findings suggest the device is intuitive, practical and well suited to the aeromedical environment.





Figure 1 Percentage of positive operator usability responses by domain. Operator usability was assessed using a five-point Likert scale. Responses of “Strongly Agree” or “Agree” were classified as positive and aggregated within each usability domain: device preparation (4 questions), participant set-up (7 questions), and scanner operation (4 questions).

Regional stroke care services overlaid with scan locations



The median scan time was 5 minutes and 7 seconds, which included a 3-minute built-in redundant scan sequence. Scan duration is expected to be significantly shorter on the production equivalent commercial device.

Several variables were logged during the research scans such as temperature, vibration, tilt angle, device motion, inflation pressure, and scan data. Importantly, the scan data quality was as expected, comparable with that of scans conducted at EMVision’s facility and not materially impacted by the demanding conditions of aeromedical transport.

Participant experience was also largely favourable, with 92% of participants indicating they felt calm during the scan and 100% indicating they would be comfortable seeing the scanner used on a family member.

Significance

The results provide real world evidence that the First Responder Brain Scanner can be operated effectively in the demanding aeromedical environment, an important target use case and future commercial opportunity for the device. The tyranny of distance has long shaped stroke outcomes where rural and remote patients wait longer for the definitive neuroimaging that determines treatment and are far less likely to receive time critical care within the treatment window, whether thrombolysis or endovascular thrombectomy for ischaemic stroke, or urgent blood pressure management and neurosurgical intervention for intracerebral haemorrhage.

Aeromedical and pre-hospital retrieval represents a critical timeframe in stroke care, where rapid neurodiagnostic information at the point of patient contact has the potential to support earlier triage, transfer and treatment decisions. The First Responder Brain Scanner is being developed to close this gap.

The final \$400,000 non-dilutive milestone payment under the Australian Stroke Alliance project, funded by the Medical Research Future Fund (MRFF) has now been received.

Co-chair of the Australian Stroke Alliance and stroke neurologist Professor Stephen Davis AO commented "This is an important step forward in providing stroke diagnosis and treatment for Australians in remote locations, flying in the ultra-lightweight and portable First Responder device from EMVision."

Dr Zoe Schofield, Head of Research Strategic Projects and Principal Investigator commented "For our flight crews, any new technology has to earn its place on the aircraft. The First Responder integrated smoothly into our retrieval workflow, our flight nurses found it intuitive to set up and operate, and importantly the scanner held up under the realities of flight. This study is a meaningful step toward bringing advanced neurodiagnostics to patients who today often have to wait many hours for a CT."

International exposure

EMVision's technology, including the First Responder, was featured in presentations at the European Stroke Organisation Conference 2026 by Dr Maren Ranhoff Hov (Oslo University Hospital) and at the PRESTO satellite meeting by Dr. Zoe Schofield (Royal Flying Doctor Service and the Australian Stroke Alliance), reflecting increasing engagement from the international clinical community and growing awareness of the Company's unique technology.

Next steps

The study achieved its primary usability and feasibility objectives, evaluating operator and patient interaction with the advanced prototype device and its deployment across real world environments. Beyond the aeromedical setting, EMVision's advanced prototype First Responder is being evaluated across complementary pre-hospital use cases. The Mobile Stroke Unit (MSU) study (Stage 1) is nearing conclusion for subsequent reporting, and preparations are well advanced for an upcoming study assessing the device in a standard road ambulance environment. Collectively, these studies are building real-world evidence across the full spectrum of pre-hospital stroke care.

Production equivalent commercial units, currently in development, are being engineered to surpass the first generation emu™ Brain Scanner across performance, usability and manufacturability informed by clinical experience, operator feedback, and learnings from multiple clinical studies. These production equivalent First Responder units will support subsequent data collection and diagnostic performance and substantial equivalence testing to progress along the regulatory pathway.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Melanie Singh
NWR Communications
+61 (0) 439 748 819
melanie@nwrcommunications.com.au

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

About Stroke

Stroke is a medical emergency that occurs when blood flow to part of the brain is interrupted, either by a blocked vessel (ischemic stroke) or bleeding into the brain (hemorrhagic stroke). The resulting lack of oxygen and nutrients can rapidly damage brain tissue, leading to disability or death if not treated promptly. Different stroke types require different types of care. Early recognition and fast access to diagnosis and appropriate care are critical, as timely intervention can significantly improve outcomes.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice

be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.

For personal use only